Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1.

Division of Molecular Biology, Beckman Research Institute of The City of Hope, Duarte, California 91010, USA.
Molecular Therapy (Impact Factor: 6.43). 07/2008; 16(6):1113-9. DOI: 10.1038/mt.2008.54
Source: PubMed

ABSTRACT Hammerhead ribozymes have been shown to silence human immunodeficiency virus-1 (HIV-1) gene expression by site-specific cleavage of viral mRNA. The two major factors that determine whether ribozymes will be effective for post-transcriptional gene silencing are colocalization of the ribozyme and the target RNAs, and the choice of an appropriate target site on the mRNA. An effective screening strategy for potential targets on the viral genome is the use of ribozyme libraries in cell culture. Capitalizing on previous findings that HIV-1 and ribozymes can be colocalized in the nucleolus, we created a novel hammerhead ribozyme library by inserting hammerhead ribozymes with fully randomized stems 1 and 2 into the body of the U16 small nucleolar RNA (snoRNA). Following three rounds of cotransfection with an HIV-1 proviral DNA harboring the herpes simplex virus thymidine kinase (HSV-TK) gene, we selected for gancyclovir-resistant cells and identified a ribozyme sequence that could potentially target both the U5 and gag genes of HIV-1 regions on the HIV-1 genome through partial homologies with these targets. When the ribozymes were converted to full complementarity with the targets, they provided potent inhibition of HIV-1 replication in cell culture. These results provide a novel approach for identifying ribozyme targets in HIV-1.

Download full-text


Available from: John J Rossi, Jun 22, 2015
  • Source
    • "a particular cellular phenotype—usually, modulation of the production of a genetic reporter. Phenotype selections have previously been used to select or optimize RNA-based regulators such as gene-targeting HHRzs (Unwalla et al. 2008), allosteric HHRzs (Wieland and Hartig 2008), transsplicing Group I introns (Ayre et al. 2002), riboswitches (Lynch et al. 2007; Nomura and Yokobayashi 2007), and transcription activators (Buskirk et al. 2004). However, the transformation of common experimental organisms such as Escherichia coli or yeast usually limits the pool size in an in vivo phenotype selection to only 10 6 –10 7 variants (compared with upward of 10 14 variants in many in vitro selection experiments). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Selection may prove to be a powerful tool for the generation of functional RNAs for in vivo genetic regulation. However, traditional in vitro selection schemes do not mimic physiological conditions, and in vivo selection schemes frequently use small pool sizes. Here we describe a hybrid in vitro/in vivo selection scheme that overcomes both of these disadvantages. In this new method, PCR-amplified expression templates are transfected into mammalian cells, transcribed hammerhead RNAs self-cleave, and the extracted, functional hammerhead ribozyme species are specifically amplified for the next round of selection. Using this method we have selected a number of cis-cleaving hammerhead ribozyme variants that are functional in vivo and lead to the inhibition of gene expression. More importantly, these results have led us to develop a quantitative, kinetic model that can be used to assess the stringency of the hybrid selection scheme and to direct future experiments.
    RNA 09/2009; 15(11):2035-45. DOI:10.1261/rna.1635209 · 4.62 Impact Factor
  • Source
    EMBO Reports 01/2009; 10(1):35-40. DOI:10.1038/embor.2008.230 · 7.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The HER-2 proto-oncogene (also called c-erbB-2/neu) encodes the protein, p185, which is closely related to the growth and metastasis of adenocarcinoma, and is overexpressed in 25-30% of human breast cancers. In this study, we attempt to reverse the malignant phenotype of the breast cancer cell line, MCF-7, using a HER-2-specific hammerhead ribozyme. Two anti-HER-2 hammerhead ribozymes, RZ1 and RZ2, were synthesized, inserted separately into the nonviral eukaryotic expression vector, pcDNA3.1(-), and transfected into MCF-7 cells. Analyses showed that the HER-2 mRNA and p185, as well as oncogene k-ras were down-regulated remarkably in the ribozyme-transfected cells, while the onco-suppressor gene, p53, was up-regulated. Furthermore, the tumorigenicity of the RZ1-stably transfected MCF-7 cells was decreased dramatically in nude mice. These results demonstrate that the use of anti-HER-2 ribozymes may be a beneficial strategy for gene therapy of breast cancer.
    Molecular Biology Reports 06/2009; 37(3):1597-604. DOI:10.1007/s11033-009-9569-4 · 1.96 Impact Factor